readthroughSign in
Nov 13, 2026Regulatory decision

Tonix sues Dr. Reddy's over generic TONMYA patent challenge

Tonix Pharmaceuticals filed a patent infringement complaint against Dr. Reddy's Laboratories in New Jersey federal court on November 13, 2026, triggering a potential 30-month stay on FDA approval of the generic.

Tonix Pharmaceuticals Holding Corp. filed a complaint for patent infringement against Dr. Reddy's Laboratories Ltd. and Dr. Reddy's Laboratories, Inc. (collectively "DRL") in the United States District Court for the District of New Jersey on November 13, 2026, according to a Form 8-K filed the same day.

The litigation stems from an earlier notice. On October 1, 2026, Tonix received a notice from DRL stating that DRL filed an Abbreviated New Drug Application containing a Paragraph IV patent certification with the FDA for a generic version of Tonix's drug, TONMYA (cyclobenzaprine hydrochloride) sublingual tablets, 2.8 mg.1 The Paragraph IV certification was made with respect to U.S. Patent Nos. 9,636,408, 9,956,188, 10,117,936 and 10,864,175, which are listed in the FDA's Orange Book.1 A Paragraph IV certification represents the generic applicant's assertion that the listed patent is invalid, unenforceable, or will not be infringed by the generic product.1

In its complaint, Tonix alleges that by filing the ANDA, DRL has infringed certain of the company's Orange Book-listed patents, and seeks an order that the effective date of FDA approval of the ANDA be no earlier than the expiration of the last to expire of the asserted patents.1

The timely filing of the complaint triggers a statutory stay of final FDA approval of DRL's ANDA for up to 30 months, subject to applicable exceptions and court orders.1

The filing was signed by Bradley Saenger, Tonix's Chief Financial Officer, on November 13, 2026.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.